3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER
8
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Prostatic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Glioblastoma
2
Colorectal Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Prostate Adenocarcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Liver Neoplasms
1
Gliosarcoma
1
Glioma
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Brain Diseases
1
Adenocarcinoma
1
Interventions
Dexamethasone
64
Lenalidomide
34
pomalidomide
33
Cyclophosphamide
33
Rituximab
31
Bortezomib
29
venetoclax
27
fludarabine
26
Gemcitabine
21
carfilzomib
20
Paclitaxel
19
pembrolizumab
17
daratumumab
16
Cisplatin
16
Carboplatin
15
Calcium Dobesilate
14
Azacitidine
14
ibrutinib
12
Docetaxel
12
Cytarabine
12
obinutuzumab
11
Nivolumab
11
durvalumab
10
Doxorubicin
10
Bevacizumab
10
selinexor
9
cemiplimab
9
blinatumomab
9
Injections
9
Cetuximab
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Recurrence
×
Radiosurgery
×
Clear all
NCT05900908
2025-04-10
PATHWAyS
GT Medical Technologies, Inc.
Phase 4
Withdrawn